Two weeks ago, members of this division appeared in front of Congress to defend their handling of a failed diabetes drug developed by Bristol and Merck.
First, our Investment Banking Division, which is the front end of the firm and has always focused on the largest companies, is also increasingly focused on medium sized companies.